DC-EZ-XBRL-SOLUTIONS
Ez-XBRL Solutions, a global leader in Financial Regulatory Compliance and Financial Analytics, is excited to announce the launch of its ground-breaking ESG platform. With the collaboration of industry experts, rating agencies, governing bodies, and regulators, and powered by advanced technologies like Artificial Intelligence (AI) and Natural Language Processing (NLP), Integix ESG sets a new standard for delivering unparalleled value to customers.
This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20230613610318/en/
Ez-XBRL launches innovative platform Integix ESG, revolutionizing ESG Reporting (Graphic: Business Wire)
Integix ESG offers a highly intuitive and process-driven flow, empowering customers to effortlessly understand and implement their ESG programs. Going beyond mere compliance, our solution focuses on creating genuine value, transparency, and meaningful insights for all stakeholders.
Aneet Kumar, President EZ XBRL Solutions said:
"We recognize the significant challenges organizations face when it comes to ESG Reporting, with multiple frameworks, evolving regulations, and intricate data management. That's why Integix ESG provides comprehensive insights, benchmarks, actionable recommendations, and a well-defined process flow to help organizations communicate their ESG impact accurately and reliably. Our platform empowers businesses to navigate these complexities, make informed decisions, and drive sustainable practices."
By harnessing the collective expertise of industry leaders and leveraging cutting-edge technologies, Integix ESG enables businesses to navigate the complexities ESG reporting effectively. The platform empowers organizations to:
- Gain Comprehensive Insights: Through deep insights into ESG performance, advanced analytics and data-driven intelligence, customers can make informed decisions and drive sustainable practices.
- Benchmark Performance: Organizations can benchmark their ESG performance against industry peers and best practices providing a clear understanding of strengths, weaknesses, and areas for improvement, fostering continuous growth and innovation.
- Access Actionable Recommendations: By providing actionable recommendations tailored to each organization's unique circumstances, empowers businesses to enhance their ESG strategies and drive positive change within their operations.
- Streamline Reporting Process: Simplifies the complex ESG reporting process, ensuring accuracy and reliability while also enabling organizations to efficiently collect, manage, and report ESG data, saving valuable time and resources.
- Harness integrated Structured Data: Provides integrated XBRL tagging capability and expertise to ensure compliance as well as provide insights through data analytics.
With Integix ESG, businesses can unlock the full potential of their ESG programs and seamlessly align financial regulatory compliance and analytics with ESG responsibilities.
To learn more visit us at www.Integixesg.com
To view this piece of content from cts.businesswire.com, please give your consent at the top of this page.
View source version on businesswire.com: https://www.businesswire.com/news/home/20230613610318/en/
About Business Wire
Subscribe to releases from Business Wire
Subscribe to all the latest releases from Business Wire by registering your e-mail address below. You can unsubscribe at any time.
Latest releases from Business Wire
Vertex Receives CHMP Positive Opinion for ALYFTREK®, a New Once-Daily CFTR Modulator for the Treatment of Cystic Fibrosis28.4.2025 08:03:00 CEST | Press release
- ALYFTREK®(deutivacaftor/tezacaftor/vanzacaftor) recommended for people with CF ages 6 years and older with at least one non-class I mutation in the CFTR gene -- In head-to-head clinical trials, deutivacaftor/tezacaftor/vanzacaftor was non-inferior on ppFEV1 and superior compared to KAFTRIO® (ivacaftor/tezacaftor/elexacaftor) at reducing sweat chloride - Vertex Pharmaceuticals (Nasdaq: VRTX) today announced that the European Medicines Agency’s (EMA) Committee for Medicinal Products for Human Use (CHMP) adopted a positive opinion for ALYFTREK®(deutivacaftor/tezacaftor/vanzacaftor)for the treatment of people with cystic fibrosis (CF) ages 6 years and older who have at least one non-class I mutation in the cystic fibrosis transmembrane conductance regulator (CFTR) gene. “Our goal has always been to serially innovate to help people with cystic fibrosis live healthier and longer lives. If approved, this new medicine would be indicated for people with CF ages 6 years and older with at least
Prilenia Enters into a Collaboration and License Agreement with Ferrer for the Commercialization and Co-Development of Pridopidine in Europe and Other Select Markets28.4.2025 07:02:00 CEST | Press release
-- Total deal size of approximately €500 million, including approximately €125 million in upfront and near-term milestones ---- Ferrer to commercialize pridopidine in Europe and other select markets; Prilenia retains full commercialization and development rights to pridopidine in North America, Japan and Asia Pacific ---- Co-development agreement in the territory supports further expansion of pridopidine in Huntington’s disease, amyotrophic lateral sclerosis and future indications ---- Pridopidine for Huntington’s disease is currently under review by the European Medicines Agency (EMA) with a CHMP opinion expected in the second half of 2025 -- Prilenia Therapeutics B.V., a biopharmaceutical company driven by an unwavering commitment to scientific excellence and accelerating progress for people affected by Huntington’s disease (HD) and amyotrophic lateral sclerosis (ALS), today announced that it has entered into a collaboration and license agreement with Ferrer for the commercialization
Ferrer Enters Into a Collaboration and License Agreement With Prilenia for the Commercialization and Co-Development of Pridopidine28.4.2025 07:00:00 CEST | Press release
Ferrer, an international B Corp pharmaceutical company with an increasing focus on rare neurological diseases, and Prilenia Therapeutics B.V.,a clinical-stage biotech company, have announced the signing of a strategic co-development and license agreement in which Ferrer obtains the rights to develop, manufacture and commercialize Pridopidine in the European Region, the Middle East and North African Region, the Southern African Region, the Central and South American Region, and the Commonwealth of Independent States Region. Pridopidine, a potent and highly selective, orally administered sigma-1 receptor agonist, designed to regulate key neuroprotective mechanisms that are often impaired in neurodegenerative diseases, is a promising candidate for the treatment of Huntington’s Disease (HD), a rare inherited neurodegenerative disease, with a high unmet medical need1. It has been studied in more than 1,700 people and long-term safety data of up to 7 years duration are available from previou
Innorna Announces FDA Rare Pediatric Disease and Orphan Drug Designations Granted to IN013 for Treatment of Wilson Disease27.4.2025 11:36:00 CEST | Press release
Innorna, a clinical-stage biotechnology company revolutionizing mRNA therapeutics with its innovative lipid nanoparticle (LNP) delivery technology, today announced the U.S. Food and Drug Administration (FDA) has granted both Rare Pediatric Disease Designation (RPDD) and Orphan Drug Designation (ODD) to its investigational mRNA therapy, IN013, for treating Wilson Disease (WD). This dual achievement accelerates the clinical development of IN013, advancing Innorna’s mission to deliver transformative therapies for WD patients. About FDA Designations The Rare Pediatric Disease Designation (RPDD) incentivizes therapies for serious or life-threatening diseases affecting fewer than 200,000 U.S. patients, primarily those aged 18 or younger. Sponsors may qualify for a Priority Review Voucher (PRV) upon approval to expedite FDA review of a subsequent drug application. The Orphan Drug Designation (ODD) supports therapies targeting rare diseases (affecting fewer than 200,000 U.S. patients) by provi
Everen Specialty Appoints Carla Greaves Chief Underwriting Officer25.4.2025 19:00:00 CEST | Press release
Everen Specialty, a Bermuda-based (re)insurer for energy markets worldwide, today announced the appointment of Carla Greaves as its new Chief Underwriting Officer (CUO). This press release features multimedia. View the full release here: https://www.businesswire.com/news/home/20250425273777/en/ Carla Greaves Ms. Greaves will join the Executive Leadership Team of the Everen Group, based in the Bermuda office, later this year. She succeeds Jane Peterson, Interim CUO, who will continue in a consultancy capacity to facilitate the transition. With more than 30 years of underwriting and leadership experience in the (re)insurance industry, Ms. Greaves brings a wealth of expertise and a proven track record of success in the Casualty market where she is recognized for building high-performing teams, driving profitable growth, and successfully navigating complex market environments. Prior to joining Everen Specialty, Ms. Greaves held increasingly senior leadership positions, most recently servin
In our pressroom you can read all our latest releases, find our press contacts, images, documents and other relevant information about us.
Visit our pressroom